Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Harrison GH et al. | 1997 | intact cell/cell culture, A172 (human glioblastoma cells), MCF7 WT(human breast cancer cell line) and HeLa S3 (human cervical carcinoma cell line) | magnetic field, 50/60 Hz | 2 mT |
Hasanzadeh H et al. | 2014 | intact cell/cell culture, SH-SY5Y (human neuroblastoma cell line) | magnetic field, 50/60 Hz | 2 mT |
Heidari S et al. | 2021 | intact cell/cell culture, human adenocarcinoma gastric cancer cell line (AGS) | 50/60 Hz, magnetic field | 0.2–2 mT |
Hemmati M et al. | 2014 | animal, mouse/Balb/c (embryo), whole body: <i>in utero</i> | magnetic field, 50/60 Hz | 0.5 mT |
Henderson B et al. | 2006 | intact cell/cell culture, human umbilical venous endothelial cells | magnetic field, 50/60 Hz | 10–700 µT |
Heredia-Rojas JA et al. | 2010 | intact cell/cell culture, INER-37 (human non-small-cell lung cancer cell line) and RMA E7 cells (E7-transfected mouse RMA lymphoma cells), transfected with the plasmid pEMF (electromagnetic field plasmid containing hsp70 promotor and the luciferase gene as reporter gene) | magnetic field, 50/60 Hz | 8–80 µT |
Hilz FM et al. | 2014 | intact cell/cell culture, primary articular chondrocytes (from calf fetlock joints) | magnetic field, 50/60 Hz, co-exposure | 1–3 mT |
Hong MN et al. | 2012 | - | magnetic field, 50/60 Hz | - |
Huang CY et al. | 2014 | intact cell/cell culture, HaCaT cells (human keratinocytes) partially transfected with CHK2 siRNA | magnetic field, 50/60 Hz, shielding/field deprivation | 1.5 mT |
Huang CY et al. | 2014 | intact cell/cell culture, human epidermal keratinocytes (derived from neonatal foreskin) and HaCaT cells (human keratinocytes) | magnetic field, 50/60 Hz | 1.5 mT |
Huwiler SG et al. | 2012 | bacterium, <i>Escherichia coli</i>/K12 MG1655 | magnetic field, 50/60 Hz, power transmission line | 1 mT |
Isaković J et al. | 2024 | intact cell/cell culture, neural stem cells derived from B6 albino mouse embryos | magnetic field, 50/60 Hz, signals/pulses | - |
Jahreis GP et al. | 1998 | intact cell/cell culture, CEM-CM3 (human acute lymphoblastic leukemia) cells | magnetic field, 50/60 Hz | 0.1 mT |
Jang YW et al. | 2019 | - | magnetic field, 50/60 Hz | - |
Jedrzejczak-Silicka M et al. | 2021 | intact cell/cell culture, L929 cells (murine fibroblast cells) and HaCaT cells (human keratinocytes cell line) | magnetic field, 50/60 Hz, low frequency | 5.9–28.4 mT |
Jeong WY et al. | 2017 | - | magnetic field, 50/60 Hz, co-exposure | - |
Jiang Y et al. | 2016 | animal, rat/Sprague Dawley | magnetic field, signals/pulses, 50/60 Hz | 4 mT |
Jin M et al. | 1997 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells), two different populations: Columbia University Cancer Center (CUCC), American Type Culture Collection (ATCC) | magnetic field, 50/60 Hz | 8 µT |
Junkersdorf B et al. | 2000 | invertebrate, nematode (<i>Caenorhabditis elegans</i>)/pPCZ1 and pD2047 | magnetic field, 50/60 Hz, co-exposure | 50–200 µT |
Kabacik S et al. | 2013 | animal, mouse/C57BL/6, whole body | magnetic field, 50/60 Hz | 100 µT |
Kanitz MH et al. | 2007 | intact cell/cell culture, SF767 (human glioma cell line) | magnetic field, 50/60 Hz, electrotherapy, therapeutic/medical device | 1.2 µT |
Karabakhtsian R et al. | 1994 | intact cell/cell culture, HL-60 (human acute myeloid leukaemia cells) | magnetic field, 50/60 Hz | 8 µT |
Karimi A et al. | 2022 | intact cell/cell culture, human malignant melanoma cell line (SK-MEL-37) | 50/60 Hz, magnetic field | - |
Keyan Z et al. | 2023 | animal, rat/Sprague-Dawley | magnetic field, signals/pulses, 50/60 Hz | - |
Kim HJ et al. | 2013 | intact cell/cell culture, mesenchymal bone marrow stem cells | 50/60 Hz, magnetic field | 1 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.